Platform-Based Manufacturing: A Strategic Enabler For Scaling Gene Therapies

The rapid growth of the cell and gene therapy sector is putting unprecedented pressure on developers to accelerate from discovery to commercial launch, necessitating highly scalable and consistent viral vector manufacturing. As thousands of gene therapy trials advance, platform-based manufacturing is emerging as a critical strategy to mitigate risk and enable scale. This approach utilizes templated, pre-qualified, and GMP-ready workflows—complete with standardized analytics and purification—that can be adapted across multiple therapeutic programs.

By adopting a platform-based model, developers gain the ability to accommodate novel vector designs and ensure smooth, fast tech transfer from early-stage to commercial production. This standardization reduces process variability, enhances regulatory readiness, and helps avoid costly delays. Understanding how these standardized systems are built and what to look for in a partner is key to moving your therapy forward efficiently. Discover how platform-based solutions expedite the path to GMP manufacturing.